HARMONi-6 OS data reinforces global Ph3 read-through for ivonescimab, as SMMT advances expansion beyond lung cancer
AI summary card
HARMONi-6 OS data reinforces global Ph3 read-through for ivonescimab, as SMMT advances expansion beyond lung cancer
Goldman Sachs' conference takeaways note that ivonescimab demonstrated an OS benefit versus the standard PD-1 + chemotherapy regimen in China's HARMONi-6, helping reduce uncertainty around SMMT's global HARMONi-3 and subsequent indication expansion.
- HARMONi-6 showed that ivonescimab + chemotherapy achieved an OS benefit in first-line squamous NSCLC: 27.9 months vs 23.7 months, HR 0.66, one-sided p=0.0017.
- Management believes the apparently lower benefit in the age ≥65 subgroup was mainly driven by imbalances in baseline target lesion size and brain metastases, and noted that three prior Ph3 studies support efficacy in this subgroup.
- The global Ph3 HARMONi-3 squamous NSCLC cohort is expected to report final PFS and interim OS in 2H, while final PFS for the non-squamous cohort is still expected in 1H27.
- SMMT is expanding ivonescimab into colorectal cancer, head and neck cancer, and novel-novel combinations, and may consider a large multinational partner for global commercialization.
- Goldman Sachs assigns a 12-month target price of $41, based on a weighted framework of 85% risk-adjusted DCF value of $35 and 15% theoretical M&A value of $73.
Report interpretation
Overview
This report is Goldman Sachs' conference takeaways on Summit Therapeutics Inc. following the 47th Annual Global Healthcare Conference. The discussion focuses on HARMONi-6 OS data for ivonescimab in first-line squamous NSCLC, upcoming readouts from global Ph3 HARMONi-3, expansion into indications beyond lung cancer, and potential BD or global commercialization partnership paths.
Core views
The core view is positive: as a China-only Ph3 study, HARMONi-6 is the first to show an OS benefit for the PD-1xVEGF bispecific ivonescimab + chemotherapy versus the standard PD-1 + chemotherapy regimen in first-line NSCLC, and management believes this strengthens confidence in HARMONi-3 final PFS and subsequent OS conversion. At the same time, the company continues to advance in colorectal cancer, RAS inhibitor combinations, and GSK B7-H3 ADC combinations, aiming to maintain ivonescimab's leading position in the rapidly evolving oncology treatment landscape.
Analysis framework
The report primarily analyzes the company based on management discussions, published clinical data, the global Ph3 timeline, indication expansion strategy, and valuation framework. Goldman Sachs uses the OS and PFS data from HARMONi-6 as read-through for HARMONi-3, and combines risk-adjusted DCF with theoretical M&A value to derive the 12-month target price.
Methodology notes
12-month target price
Of Goldman Sachs' 12-month target price of $41, 85% weight comes from a risk-adjusted DCF value of $35, assuming a WACC of 18% and a TGR of 2%.
M&A scenario valuation
In the target price framework, 15% weight comes from a theoretical M&A value of $73, based on 11x 2031E sales.
PFS-to-OS conversion and global Ph3 de-risking
Management believes HARMONi-6's OS HR of 0.66 and prior PFS HR of 0.60 together support conversion of ivonescimab's PFS benefit into an OS benefit and provide a positive reference for HARMONi-3.
Growth, Financial Returns, Multiple, Integrated
Goldman Sachs' factor profile compares stocks with the market and peers across growth, financial returns, valuation multiples, and integrated percentile rankings, but the main body of this report does not disclose SMMT's specific factor percentiles.
M&A likelihood rating from 1 to 3
Goldman Sachs discloses that it uses M&A Rank across its coverage to assess potential acquisition likelihood; this report's target price includes a theoretical M&A value component.
Asset mapping & comparison
Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).
- Summit Therapeutics Inc. (SMMT.O)The subject company and stock of the report.
- Strengths
- Owns global development rights to ivonescimab; HARMONi-6 OS data provide positive validation for its core asset, and the company continues to expand in lung cancer, colorectal cancer, and combination therapies.
- Weaknesses
- Interim PFS in the HARMONi-3 squamous cohort did not reach statistical significance, and global commercialization capability still needs to be proven.
- Comparison
- Relative to the existing PD-1 + chemotherapy standard regimen, the report highlights that ivonescimab + chemotherapy showed an OS advantage in HARMONi-6.
- Risks
- Global study replication risk, regulatory approval risk, competitive risk, financing dilution risk, and U.S.-China supply chain risk.
- ivonescimab (ivo, PD-1xVEGF)SMMT's core oncology pipeline asset.
- Strengths
- HARMONi-6 showed OS and PFS advantages, and Ph2 colorectal cancer data disclosed a 9-month PFS rate of 76.1%.
- Weaknesses
- Commercial value depends on subsequent global Ph3 results, indication expansion, and continued safety validation.
- Comparison
- The report compares it with the Tevimbra/PD-1 + chemotherapy standard regimen as well as other competing PD-1/L1xVEGF assets.
- Risks
- Competing assets may show superior data or advance clinical development more quickly.
- AkesoSMMT's partner and the source of China's HARMONi-6 data.
- Strengths
- Has shared HARMONi-6 OS data and supported market recognition of ivonescimab's mechanism and efficacy.
- Weaknesses
- China-only regional data may not fully translate to SMMT's global clinical studies.
- Comparison
- Akeso data are used as positive read-through for the global HARMONi-3 study.
- Risks
- Cross-regional clinical, regulatory, and supply chain differences may affect judgments on global commercialization.
- RVMD RAS inhibitors and GSK B7-H3 ADC combination regimensA novel-novel combination development direction for ivonescimab.
- Strengths
- Provide an expansion path for ivonescimab into more solid tumors and combination treatment settings.
- Weaknesses
- The related studies are still in early stages or about to begin dosing, with limited clinical certainty.
- Comparison
- This is a combination strategy distinct from traditional PD-1 + chemotherapy.
- Risks
- Early combination therapies may face uncertainty in efficacy, safety, dosing, and indication selection.
Key data
- HARMONi-6 OS27.9 months vs 23.7 months; HR 0.66; 95% CI 0.50-0.87; one-sided p=0.0017ivonescimab + chemotherapy demonstrated a statistically significant and clinically meaningful OS benefit versus Tevimbra + chemotherapy in a China Ph3 study in first-line squamous NSCLC.
- HARMONi-6 PFSHR 0.60Management uses the previously disclosed PFS data from ESMO together with the latest OS data as read-through for HARMONi-3.
- Timing for HARMONi-3 squamous NSCLC cohort2HFinal PFS and interim OS are expected; the company acknowledges that interim OS may not reach statistical significance, but hopes to see a trend supporting an ultimately significant outcome.
- Timing for HARMONi-3 non-squamous NSCLC cohort1H27Enrollment completion has been pulled forward to this month, and final PFS analysis remains scheduled for 1H27.
- Ph2 colorectal cancer data9-month PFS rate 76.1%; Ph3 dose 20mg/kgManagement believes the data for ivonescimab + mFOLFOX6 in metastatic colorectal cancer are differentiated and support global Ph3 HARMONi-GI3.
- Combination therapy pipelineRAS inhibitors + ivonescimab; GSK B7-H3 ADC + ivonescimabThe RAS inhibitor combination study in partnership with RVMD is advancing in solid tumors; the study combining GSK B7-H3 ADC is planned to begin dosing in mid-2026.
- Target price$4112-month target price based on a weighted combination of risk-adjusted DCF and theoretical M&A value.
- Disclosed price$14.77The price for Summit Therapeutics Inc. listed in regulatory disclosures.
- DCF assumptionsWACC 18%; TGR 2%; DCF value $35DCF carries an 85% weight in the target price.
- M&A valuation assumptionsTheoretical M&A value $73; 11x 2031E salesM&A value carries a 15% weight in the target price.
Impact & implications
If HARMONi-3 can confirm the PFS and OS advantage suggested by HARMONi-6, the credibility of ivonescimab's global commercialization will be significantly enhanced and may increase interest from large multinational pharma partners or acquirers. Conversely, if the China data cannot be replicated in the global study, or competing PD-1/L1xVEGF assets deliver superior data earlier, SMMT's valuation and commercialization path would face meaningful downside risk.
Risks
- Data generated by Akeso in China may not translate into SMMT's global clinical study results.
- U.S.-China trade relations may affect supply chain operations.
- Unexpected safety issues or clinical delays may postpone time to market.
- If regulatory approval is not obtained in certain indications or regions, commercial success and sales forecasts will be impaired.
- Competing PD-1/L1xVEGF assets may disclose superior data or advance clinical development more quickly.
- Financing risk and equity dilution risk.
What to watch
- Final PFS and interim OS results for the HARMONi-3 squamous NSCLC cohort in 2H.
- Completion of enrollment for the HARMONi-3 non-squamous NSCLC cohort and the 1H27 final PFS analysis.
- Progress of the global Ph3 HARMONi-GI3 colorectal cancer study.
- Early data from the RAS inhibitors + ivonescimab and GSK B7-H3 ADC + ivonescimab combination studies.
- Whether management introduces a large multinational pharma partner to accelerate global commercialization.
- Whether global Ph3 OS data become a key catalyst for further de-risking and potential BD.